Seminars in arthritis and rheumatism最新文献

{"title":"The association of cervical and lumbar mobility with functional ability in axial spondyloarthritis: Insights from the CASTRO registry using Inertial Measurement Unit system","authors":"Diana Maria Margareta Moldovan ,&nbsp;I. Concepción Aranda-Valera ,&nbsp;Lourdes Ladehesa-Pineda ,&nbsp;María Carmen Ábalos-Aguilera ,&nbsp;María Ángeles Puche-Larrubia ,&nbsp;Alejandro Escudero-Contreras ,&nbsp;Cristina González-Navas ,&nbsp;Juan Luis Garrido-Castro ,&nbsp;Daniela Fodor ,&nbsp;Eduardo Collantes-Estévez ,&nbsp;Clementina López-Medina","doi":"10.1016/j.semarthrit.2025.152703","DOIUrl":"10.1016/j.semarthrit.2025.152703","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to evaluate the association of cervical and lumbar mobility with functional ability in patients with axial spondyloarthritis (axSpA) using an inertial measurement unit (IMU) sensor system, as well as the influence of disease duration on this association.</div></div><div><h3>Methods</h3><div>This cross-sectional study included 156 patients with axSpA from the Córdoba axSpA Task Force Registry and Outcomes (CASTRO) registry. Spinal mobility was assessed with the IMU system and functional ability was measured using the Bath Ankylosing Spondylitis Functional Index (BASFI). Patients were categorized into non-longstanding (≤23 years) and longstanding (&gt;23 years) groups based on the median disease duration. Univariable and multivariable linear regressions were conducted to evaluate the variability of BASFI explained by each spinal movement (coefficient of determination [R²]).</div></div><div><h3>Results</h3><div>Multivariable linear regression analysis showed that cervical movements collectively explained 19.9 % (R² = 0.199) of BASFI variability, while lumbar mobility accounted for 11.3 %. Among longstanding axSpA patients, cervical rotation (unstandardized regression coefficient [<em>B</em>] = -0.68, 95 % CI1.13 to -0.24) and lumbar flexion (<em>B</em> = 0.65, 95 % CI 0.05 to 1.24), were independently associated with the BASFI scores. In non-longstanding patients, lumbar mobility, particularly lumbar rotation (<em>B</em> = -0.51, 95 % CI0.97 to -0.05), showed a stronger association with functional ability.</div></div><div><h3>Conclusions</h3><div>This study suggests that cervical mobility is more strongly associated with functional ability than lumbar mobility in axSpA patients. However, the impact of cervical and lumbar mobility on functional ability varies with disease duration.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152703"},"PeriodicalIF":4.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenesis and targets in uveitis","authors":"Professor Athimalaipet V Ramanan","doi":"10.1016/j.semarthrit.2025.152692","DOIUrl":"10.1016/j.semarthrit.2025.152692","url":null,"abstract":"<div><div>Uveitis is the most common ocular finding in systemic rheumatic diseases. It is a potentially sight threatening disease seen on its own or in association with systemic rheumatic diseases. Whilst significant advances have been made with biological and small molecular therapies for conditions such as rheumatoid arthritis (RA), ankylosing spondylisitis (AS), juvenile idiopathic arthritis (JIA) and psoriatic arthritis (PsA), the evidence base for managing the ocular complications from these diseases, particularly uveitis, is still limited.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152692"},"PeriodicalIF":4.6,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is mixed connective tissue disease (MCTD) a subtype of systemic sclerosis?","authors":"Yoshiya Tanaka","doi":"10.1016/j.semarthrit.2025.152678","DOIUrl":"10.1016/j.semarthrit.2025.152678","url":null,"abstract":"<div><div>In 1972, mixed connective tissue disease (MCTD) was proposed by Sharp et al. as a disease entity characterized by overlapping clinical features of systemic lupus erythematosus, systemic sclerosis (SSc), and polymyositis, as well as high titers of serum anti-U1-RNP antibody. However, the disease concept of MCTD is sometimes far from being sufficiently acknowledged. We, therefore, reported the revised diagnostic criteria for MCTD 2019 by consensus method and evaluation using clinical data of typical and borderline cases of MCTD. The disease entity of MCTD and its difference from SSc can be further emphasized by 1) microvasculopathy detected using nailfold videocapillaroscopy, 2) statistical clustering based on immunophenotypic analysis using flow cytometry, 3) immune cell-specific gene regulation, 4) clinical relevance of anti-SMN complex antibodies.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152678"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in APS pregnancy: Results from the IMPACT trial","authors":"Jane E. Salmon ,&nbsp;Marta Guerra ,&nbsp;Mimi Kim ,&nbsp;D. Ware Branch","doi":"10.1016/j.semarthrit.2025.152689","DOIUrl":"10.1016/j.semarthrit.2025.152689","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152689"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial disparity of lung cancer risk in people with rheumatoid arthritis","authors":"Yi-Sheng Jhang ,&nbsp;Yu-Jung Su ,&nbsp;Hui-Chin Chang ,&nbsp;Shih-Chi Yang ,&nbsp;Shiu-Jau Chen ,&nbsp;Shuo-Yan Gau","doi":"10.1016/j.semarthrit.2025.152702","DOIUrl":"10.1016/j.semarthrit.2025.152702","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152702"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing the PEIR Framework and PEIRS-22 to facilitate improved and sustainable patient engagement in OMERACT","authors":"Caitlin Jones ,&nbsp;Clayon Hamilton ,&nbsp;Peter Tugwell ,&nbsp;Shawna Grosskleg ,&nbsp;Catherine Hofstetter ,&nbsp;Ben Horgan ,&nbsp;Alison Hoens ,&nbsp;Dorcas Beaton","doi":"10.1016/j.semarthrit.2025.152704","DOIUrl":"10.1016/j.semarthrit.2025.152704","url":null,"abstract":"<div><h3>Background</h3><div>OMERACT (Outcome Measures in Rheumatology) is an international initiative focused on improving outcome measurement in rheumatology research, fostering collaboration among PRPs, clinicians, and researchers to develop Core Outcome Sets. The 22-item Patient Engagement In Research Scale (PEIRS-22) is a tool designed to measure the level of meaningful patient engagement and guide efforts towards improvement.</div></div><div><h3>Aim</h3><div>1) To describe the current profile of patient engagement at OMERACT using the scores generated by the PEIRS-22 and 2) to assess the validity of the PEIRS-22 within the OMERACT group of PRPs.</div></div><div><h3>Methods</h3><div>We administered the PEIRS-22 to assess the level of meaningful engagement of PRPs with OMERACT. We compared the scores with self-rated participant engagement, and asked open ended questions to investigate the validity of the tool in the OMERACT PRP population.</div></div><div><h3>Results</h3><div>Overall engagement was meaningful and correlated to self-reported level of engagement. However, there were components and items that were flagged as priorities for improvement (Convenience, Benefits and Team Environment, and specifically items PR11: I participated in making decisions about the project, T2: I was an equal partner in the research project team, and SU1: I received sufficient support to contribute to the project.</div></div><div><h3>Conclusion</h3><div>This study highlights the validity of the PEIRS-22 within OMERACT and reveals satisfactory levels of meaningful PRP engagement. As OMERACT continues to learn and evolve, the PEIRS-22 will be integral in developing a structured and consistent approach to patient engagement.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152704"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143549205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remission in gout is possible: 5-year follow-up in the NOR-Gout study","authors":"Till Uhlig ,&nbsp;Johan Stjärne ,&nbsp;Lars Fridtjof Karoliussen ,&nbsp;Joe Sexton ,&nbsp;Tron Eskild ,&nbsp;Sella Aarrestad Provan ,&nbsp;Espen André Haavardsholm ,&nbsp;Hilde Berner Hammer","doi":"10.1016/j.semarthrit.2025.152698","DOIUrl":"10.1016/j.semarthrit.2025.152698","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the performance of remission definitions for gout in an observational treat-to-target patient cohort with 5 years of follow-up.</div></div><div><h3>Methods</h3><div>Inclusion criteria were crystal proven gout with increased serum urate levels and a flare. Remission was determined according to the 2016 preliminary gout remission definition, a modified preliminary definition with more lenient thresholds for the individual variables pain due to gout and patient global assessment of gout disease activity, and the simplified definition without patient reported outcomes. Linear mixed models were used to compare quality of life with SF-36 physical (PCS) and mental (MCS) components and structural damage with semiquantitative dual energy tomography (DECT) across patients fulfilling and not fulfilling each remission definition.</div></div><div><h3>Results</h3><div>Data were analysed from 211 patients (mean age 56.4 years, 95.3 % males) included in an intensive one-year treat-to-target intervention with follow-up at 1, 2, and 5 years. The frequency of remission increased for both the preliminary definition at 1, 2 and 5 years (4.6 %, 22.1 %, and 42.8 %), the modified preliminary definition (5.1 %, 28.4 %, and 44.1. %) and the simplified definition (7.7 %, 45.4 %, and 58.6 %)(<em>p</em> &lt; 0.001 for all definitions). The simplified definition identified more patients in remission than the preliminary and the modified preliminary definition at years 2 and 5. All three definitions discriminated for SF-36 MCS, PCS or DECT.</div></div><div><h3>Conclusion</h3><div>Remission in gout after urate lowering therapy was seldom after 1 but high after 5 years and was highest for the simplified definition. Remission definitions showed concurrent validity for quality of life and structural changes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152698"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant cell arteritis – New treatment targets at the horizon","authors":"Jens Thiel","doi":"10.1016/j.semarthrit.2025.152686","DOIUrl":"10.1016/j.semarthrit.2025.152686","url":null,"abstract":"<div><div>Increasing insights into the pathogenesis of giant cell arteritis (GCA) identified a large number of new treatment targets. Very recently clonal hematopoesis, immune ageing processes associated with inflammation and dysregulated immune checkpoints have been linked to the pathogenesis of GCA. Based on pathopyhsiological insights new treatment options such as Janus kinase inhibitors or IL-17A blocking antibodies are currently tested in GCA.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152686"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set","authors":"Wils Nielsen ,&nbsp;Fadi Kharouf ,&nbsp;Carolina Munoz Grajales ,&nbsp;Aarabi Thayaparan ,&nbsp;Melanie Anderson ,&nbsp;Vibeke Strand ,&nbsp;Lee Simon ,&nbsp;Dennisse Bonilla ,&nbsp;Eric Morand ,&nbsp;Julian Thumboo ,&nbsp;Martin Aringer ,&nbsp;Marta Mosca ,&nbsp;Ian Bruce ,&nbsp;Elektra J. Papadopoulos ,&nbsp;Karina D. Torralba ,&nbsp;Laura Patricia Whitall-Garcia ,&nbsp;Cheryl F. Rosen ,&nbsp;Ioannis Parodis ,&nbsp;Alfred Kim ,&nbsp;Maya Desai ,&nbsp;Zahi Touma","doi":"10.1016/j.semarthrit.2025.152684","DOIUrl":"10.1016/j.semarthrit.2025.152684","url":null,"abstract":"<div><h3>Objective</h3><div>To identify candidate Systemic Lupus Erythematosus (SLE) domains from the literature for consideration towards the development of the SLE Core Outcome Set.</div></div><div><h3>Methods</h3><div>This was a comprehensive scoping literature review of SLE clinical trials and systematic reviews published since 2010. Studies were identified from 5 databases and were screened for eligibility. Candidate domains were extracted from the included studies. Candidate domains were winnowed and binned by the Outcome Measures in Rheumatology (OMERACT) SLE Advisory Group.</div></div><div><h3>Results</h3><div>Of the 4063 studies identified, 507 met inclusion criteria and proceeded to data extraction. Multiple domains and items were extracted, which winnowing and binning reduced to 25 candidate domains.</div></div><div><h3>Conclusion</h3><div>The 25 candidate domains cover the important aspects of SLE and the 4 core areas of disease impact according to OMERACT framework. The 25 candidate domains constitute a feasible and manageable number of domains to proceed with to the core domain consensus stage that covers the wide range of impact of SLE. The candidate domains will be supplemented by ongoing qualitative research with patients living with SLE to identify additional domains before proceeding to the consensus stage.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152684"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies in anti-MDA5 antibody-positive interstitial lung disease patients: A multicenter retrospective cohort study in China","authors":"Bi Chen ,&nbsp;Bin Xi ,&nbsp;Hongxia Xin ,&nbsp;Ruyi Zou ,&nbsp;Yaqiong Tian ,&nbsp;Qi Zhao ,&nbsp;Xin Yan ,&nbsp;Xiaohua Qiu ,&nbsp;Yujuan Gao ,&nbsp;Yin Liu ,&nbsp;Min Cao ,&nbsp;Hanyi Jiang ,&nbsp;Ping He ,&nbsp;Juan Chen ,&nbsp;Hourong Cai","doi":"10.1016/j.semarthrit.2025.152700","DOIUrl":"10.1016/j.semarthrit.2025.152700","url":null,"abstract":"<div><div>The aim of this study was to assess the 2017 EULAR/ACR classification criteria performance for determining idiopathic inflammatory myopathies (IIMs) in a cohort of patients with anti-MDA5 antibody-positive IIM-related interstitial lung disease (anti-MDA5+IIM-ILD). The outcomes of patients, who did not meet the EULAR/ACR criteria, and who had interstitial pneumonia and exhibited an autoimmune phenotype associated with anti-MDA5 positivity were also investigated.</div></div><div><h3>Methods</h3><div>This retrospective study recruited adult patients from four hospitals in China who were diagnosed with anti-MDA5 antibody-positive IIM-related interstitial lung disease. Data on disease manifestations, laboratory findings, and imaging findings were collected through electronic medical records. The performance and consistency of the 2017 EULAR/ACR classification criteria were compared with those of the Bohan/Peter criteria combined with Sontheimer's CADM criteria. Additionally, this study evaluated the performance of incorporating anti-MDA5 antibodies into the EULAR/ACR criteria and explored the criteria proposed by Casal-Domingez based on myositis-specific antibodies (MSAs). Finally, clinical characteristics and prognoses were compared between patients with MDA5+IIM-ILD who met the EULAR/ACR criteria and those who did not meet the EULAR/ACR criteria.</div></div><div><h3>Results</h3><div>A total of 250 patients with anti-MDA5-related IIM-ILD, including those with dermatomyositis (DM, 23.6 %) and clinically amyopathic dermatomyositis (CADM, 76.4 %), were recruited. Of these, 175 (70 %) and 64 (25.7 %) patients met the EULAR/ACR and Bohan/Peter criteria, respectively. According to Sontheimer's CADM criteria, 60.4 % of patients could be classified according to the Bohan and Peter criteria. Thirty percent of the anti-MDA5 antibody-positive patients did not meet the EULAR/ACR criteria but met the IPAF criteria. The sensitivity of the EULAR/ACR criteria increased to 99.2 % when anti-JO-1 antibodies were replaced with anti-MDA5 antibodies. In this cohort, a sensitivity of 100 % was obtained using the Casal-Domingez criteria. There were no significant differences in clinical characteristics or prognoses between MDA5+IIM-ILD patients who met the EULAR/ACR criteria, those who did not meet the criteria, and those who met the IPAF criteria.</div></div><div><h3>Conclusion</h3><div>Approximately 30 % of clinically diagnosed anti-MDA5 antibody-positive IIM-ILD patients cannot be classified according to the EULAR/ACR criteria, suggesting that such patients should be managed as IIM-ILD patients. Modifying the existing criteria by including other MSAs, such as anti-MDA5 antibodies, as one of the scoring criteria is recommended. Future IIM guidelines should consider incorporating ILD into the diagnostic criteria.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152700"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}